 In 2020, several antibody therapies were approved for treating COVID-19, including Bamlanivimab, Casarivimab and Mdevimab, Lavilimab, Tanizumab, Margechuzimab and Olocizumab. Additionally, Proglamab and Olocizumab were approved for treating other diseases. Several antibody therapies have also been approved for treating cancer, such as Leranlimab, Tezapelumab, Ferisimab, Ligelizumab, Getosmab and Fasinumab. Furthermore, 16 antibody therapies are currently being tested in late-stage clinical trials for non-cancer indications, including 6 for COVID-19, and 44 antibody therapies are being tested in late-stage clinical trials for cancer indications. This article was authored by Helen Kaplan and Janis M. Reichert.